Skip to main content
Fig. 1 | Health Economics Review

Fig. 1

From: Comparison of post-authorisation measures from regulatory authorities with additional evidence requirements from the HTA body in Germany – are additional data requirements by the Federal Joint Committee justified?

Fig. 1

Dataset used for the analysis of conditional appraisals and PAMs

* Ipilimumab received a license expansion that resulted in an EPAR variation and a second benefit assessment. EMA: European Medicines Agency; EPAR: European Public Assessment Report; G-BA: Federal Joint Committee; PAM: post-authorisation measure

Back to article page

Health Economics Review

ISSN: 2191-1991

Contact us